ArticleClinical and experimental immunology1988
Interleukin 2 receptor in patients with localized and systemic parasitic diseases.
Article in Clinical and experimental immunology, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.Journal of cancer research and clinical oncology · 2006Article
- Serum sIL-2R, TNF-alpha and IFN-gamma in alveolar echinococcosis.World journal of gastroenterology · 2004Article
- Malaria associated apoptosis is not significantly correlated with either parasitemia or the number of previous malaria attacks.Parasitology research · 2003Article
- Gammadelta+ T cells preferentially respond to live rather than killed malaria parasites.Infection and immunity · 1998Article
- High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis.Clinical and experimental immunology · 1998Article
- Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria.Infection and immunity · 1997Article
- Immunological markers of childhood fevers in an area of intense and perennial malaria transmission.Clinical and experimental immunology · 1995Article
- Soluble plasma IL-2 receptors and malaria.Clinical and experimental immunology · 1993Article
- Interleukin-2 receptors in experimental Chagas' disease.Infection and immunity · 1992Article
- Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.The Journal of clinical investigation · 1992Article
- Modulation of the cellular immune response during Plasmodium falciparum infections in sickle cell trait individuals.Clinical and experimental immunology · 1992Article
- Levels of cytokines in plasma during Plasmodium falciparum malaria attacks.Journal of clinical microbiology · 1991Article
- Functional and phenotypic changes in human lymphocytes after coincubation with Leishmania donovani in vitro.Infection and immunity · 1990Article
- Article
- Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria.Journal of clinical microbiology · 1990Article
- Idiopathic pulmonary fibrosis: can cell mediated immunity markers predict clinical outcome?Thorax · 1990Article
- Evolution of the levels of soluble interleukin-2 receptors during Plasmodium falciparum and P. vivax malaria.Journal of clinical microbiology · 1989Article
- Soluble interleukin 2 receptor in atopic eczema.BMJ (Clinical research ed.) · 1989Article
- The therapeutic efficacy of an anti-IL-2 receptor monoclonal antibody correlates with an increase in serum soluble IL-2 receptor levels.Clinical and experimental immunology · 1989Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An enzyme-linked immunosorbent assay was used to quantify soluble interleukin 2 receptor (IL-2R) in the serum of patients with helminthic and protozoal infections. The results demonstrated that levels of IL-2R were normal in patients with helminthic infections limited to the intestinal tract (ascariasis, trichuriasis), but significantly elevated in patients with systemic or long-lasting infections (strongyloidiasis, schistosomiasis, fascioliasis, opisthorchiasis). In patients infected with Schistosoma mansoni levels of IL-2R were higher in those with the hepatosplenic than in those with the intestinal form of the disease. Patients with malaria also showed increased serum levels of IL-2R, irrespective whether the infection was caused by Plasmodium falciparum or P. vivax. No difference was observed between patients with acute or history of malaria. The highest levels of IL-2R were observed in patients with visceral leishmaniasis. Interestingly, in these patients the concentration of IL-2R correlated to specific antibody titre. The results are discussed in the context of preferential activation of T lymphocytes, B lymphocytes and/or macrophages during the course of the different parasitic infections investigated.
Indexed as
Identifiers
3136958PMC1541536W2412715193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.